Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants
- Conditions
- Chikungunya Virus
- Interventions
- Other: PlaceboBiological: VAL-181388
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03325075
- Locations
- πΊπΈ
Optimal Research, Rockville, Maryland, United States
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
- Conditions
- Relapsed/Refractory Solid Tumor Malignancies or LymphomaOvarian Cancer
- Interventions
- Biological: mRNA-2416Biological: Durvalumab
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT03323398
- Locations
- πΊπΈ
University of Colorado Hospital, Aurora, Colorado, United States
πΊπΈSmilow Cancer Hospital, New Haven, Connecticut, United States
πΊπΈNorthwestern Memorial Hospital, Indianapolis, Indiana, United States
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT03313778
- Locations
- πΊπΈ
University of Arizona, Tucson, Arizona, United States
πΊπΈAngeles Clinic and Research Institute, Los Angeles, California, United States
πΊπΈThe George Washington Cancer Center, Washington, District of Columbia, United States
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
- Conditions
- Influenza
- Interventions
- Biological: VAL-506440Other: Placebo
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT03076385
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
- Conditions
- Zika Virus
- Interventions
- Other: PlaceboBiological: mRNA-1325
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03014089